Human IL-33R (ST2) Antibody - Astegolimab Biosimilar
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hIL-33R-hIgG2 Human IL-33R/ST2 (Astegolimab) antibody - Human IgG2 |
Show product |
100 µg 3 x 100 µg |
hil33r-mab2
|
|
Anti-human IL-33R (ST2, Il-1R4, IL1RL1) - Astegolimab biosimilar - CAS #2173054-79-8
InvivoGen also offers:
Anti-hIL-33R-hIgG2 is a biosimilar antibody of Astegolimab, a human interleukin 33 receptor (IL-33R) antibody that blocks IL-33 signaling. This monoclonal antibody (mAb) targets the IL-1R4 (or ST2) subunit of the IL-33 receptor. Astegolimab is under investigation for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Anti-hIL-33R-hIgG2 comprises the variable region of Astegolimab and the IgG2 constant region of Astegolimab for mild effector functions.
This mAb can be used together with HEK-Blue™ IL-33 cells for screening and neutralization assays to block IL-33R signaling induced by recombinant human IL-33 (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Figures
Specifications
Application: Neutralization assay, ELISA
Isotype: Human IgG2, kappa
Recommended isotype control: Human IgG2
Target: Human IL-1R4 (ST2, IL-33R)
Species reactivity: Human
Clone: Astegolimab, MSTT 1041A; RG 6149
Cas number: 2173054-79-8
Sterility: 0.2 µm filtration
Source: CHO cells
Production: Animal-free
Purification: Protein A
Molecular weight: 145 kDa
Physical form: Lyophilized
Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Preservative: Azide-free
Reconstitution buffer: Sterile water (not provided)
Purity: ≥ 95 %
Quality control: Each lot is functionally tested and validated.
Back to the topContents
Anti-hIL-33R-hIgG2 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hil33r-mab2: 100 µg
- hil33r-mab2-03: 3 x 100 µg
The product is shipped at room temperature.
Upon receipt, store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year.
Avoid repeated freeze-thaw cycles.
Details
Astegolimab and IL-33 background
Astegolimab is a fully human IgG2 monoclonal antibody (mAb) that blocks interleukin 33 (IL-33) signaling by targeting the IL-1R4 (aka ST2) subunit of the IL-33 receptor [1].
IL‐33, a member of the IL‐1 cytokine family, functions as an alarmin, playing a crucial role in immune responses [2]. It is constitutively expressed and released in response to tissue injury or external stress exposure [2]. Common asthma exacerbation triggers, such as inhaled allergens and respiratory viruses, have been shown to induce IL-33 synthesis and release, directly linking IL-33 to asthma susceptibility and severity [1]. Once released, IL-33 binds to IL-33R on resident airway and inflammatory cells, initiating type 2 (T2) inflammation and pro-inflammatory cytokine production (e.g. TNF-α, IFN-γ, and IL-6), which subsequently contributes to airway inflammation and disease progression [1].
Since IL-33R is expressed on a variety of cell types involved in inflammatory diseases, including mast cells and eosinophils, Astegolimab offers a promising therapeutic approach for treating asthma and chronic obstructive pulmonary disease (COPD). [3].
References:
1. Kelsen SG, et al. 2021. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 148(3):790-798.
2. Kotani N, et al. 2022. Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma. J Clin Pharmacol. 62(7):905-917.
3. Varricchi G, Poto R, 2024. Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins. Eur J Intern Med. 125:28-31.